Refining prognosis in non-small-cell lung cancer [5]

New England Journal of Medicine

Volumn 356, Issue 2, 2007, Pages 190-

  Singh, Tejvir ^a   Dhindsa, Jasmine ^b  

^a Reno Oncology Consultants   (United States)

^b Renown Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BIOLOGICAL MODEL; GENE EXPRESSION PROFILING; LUNG TUMOR; MORTALITY; NOTE; PATHOLOGY; PROGNOSIS; SURVIVAL;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MODELS, GENETIC; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33846143882     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006;24:Suppl:7007. abstract.
2. Douillard J-Y, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. J Clin Oncol 2005;23:Suppl:7013. abstract.
3. Winton TL, Livingston R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer: (NSCLC) Intergroup JBR.10. J Clin Oncol 2004;22:Suppl:7018. abstract.